NCT03770299View on ClinicalTrials.gov

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 15, 2021

Primary Completion Date

March 14, 2023

Study Completion Date

March 14, 2024

Conditions
Non-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaCirculating Tumor DNA
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

DRUG

Vinorelbine

Specified dose on specified days

DRUG

Gemcitabine

Specified dose on specified days

DRUG

Docetaxel

Specified dose on specified days

DRUG

Pemetrexed

Specified dose on specified days

DRUG

Cisplatin

Specified dose on specified days

DRUG

Carboplatin

Specified dose on specified days

DRUG

Paclitaxel

Specified dose on specified days

OTHER

Observation

Observation by the investigator

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03770299 - An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease | Biotech Hunter | Biotech Hunter